Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Sequential development of BCR::ABL1-positive chronic myeloid leukemia during treatment of JAK2 V617F-positive essential thrombocythemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2026

Goto Midori, Higashi Takehiro, Morimoto Hiroaki, Tsukada Junichi

Abstract excerpt

We report a rare case of JAK2 V617F-positive essential thrombocythemia (ET) followed by BCR::ABL1-positive chronic myeloid leukemia (CML) in a 47-year-old woman. Dasatinib induced deep molecular remission; however, persistent thrombocytosis required hydroxyurea. The persistence of the JAK2 V617F mutation despite BCR::ABL1 suppression suggests distinct clonal populations. This case underscores the importance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ABL1 gene

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 42128863
DOI: 10.11406/rinketsu.67.328

Genes

ABL1
BCR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Sequential development of BCR::ABL1-positive chronic myeloid leukemia during treatment of JAK2 V617F-positive essential thrombocythemia].PMID 42128863Read ↗

Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.Semantic proximity Read ↗

Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.Semantic proximity Read ↗

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.Semantic proximity Read ↗

First Philippine report of myeloproliferative neoplasms with concurrent JAK2 and BCR::ABL1 mutations.Semantic proximity Read ↗

[Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review].Semantic proximity Read ↗

[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].Semantic proximity Read ↗

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.Semantic proximity Read ↗

Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis.Semantic proximity Read ↗

Isolated Extreme Thrombocytosis as the Presenting Feature of Chronic Myeloid Leukemia-An Unusual Phenotype Treated With Plateletpheresis.Semantic proximity Read ↗

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.Semantic proximity Read ↗

[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].Semantic proximity Read ↗

Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.